Mynd aims to establish the link between depression and inflammation in the brain and ultimately therapeutically target this link using compounds found in psilocybin.
The company currently hold 38 licenses for research into 38 different analogues of psilocybin which is carried out at Michael Smith Laboratories at The University of British Columbia.
MYND Life Sciences has raised a total of $1.9M in funding over 2 rounds. Their latest funding was raised on Nov 30, 2021 from a Grant round.
“Mynd is a life sciences based neuro-pharmaceutical drug development company advancing medicines that leverage psychedelic compounds. Our mission is to further our existing research and patents linking depression and inflammation at the genetic and cellular level to develop pharmaceutical treatments.”
B2B Biotech Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates